HL
HLTRF.US HLS Therapeutics Inc
- Market cap
- USD 80.4M
- P/E
- -
- P/B
- 1.46x
- ROE
- -14.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HLTRF.US undervalued?
Graham numberThe Graham number of HLS Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HLS Therapeutics Inc fundamental analysis
No fundamental analysis for HLS Therapeutics Inc yet.
HLS Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that a…
Full company profileHLS Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HLS Therapeutics Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 53.4M | 75.1M | 61.4M | 54.2M | 56.1M | 60.0M | 61.5M | 63.1M | 56.6M | 56.5M | 55.0M |
| Gross Profit | 104K | 70.9M | 58.8M | 52.2M | 52.5M | 56.0M | 56.5M | 55.5M | 47.6M | 24.0M | 29.5M |
| Operating Income | -1.26M | 23.3M | 7.64M | -4.63M | -12.1M | -6.28M | -13.4M | -10.3M | -7.69M | -4.18M | -5.49M |
| EBITDA | -1.26M | 55.2M | 39.3M | 19.7M | 22.7M | 25.5M | 18.6M | 12.9M | 17.2M | 18.0M | 17.6M |
| Net Income | -875K | -6.10M | -24.8M | -19.6M | -15.3M | -13.1M | -23.6M | -27.5M | -19.7M | -12.6M | -7.30M |
| EPS | -0.04 | -0.24 | -0.92 | -0.67 | -0.48 | -0.41 | -0.73 | -0.85 | -0.62 | -0.40 | -0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 25.5M | 385M | 306M | 320M | 304M | 276M | 242M | 209M | 160M | 137M | 120M |
| Total Liabilities | 552K | 204M | 148M | 141M | 135M | 115M | 116M | 111M | 88.6M | 75.7M | 69.7M |
| Shareholders' Equity | 25.0M | 180M | 158M | 178M | 169M | 161M | 125M | 97.7M | 71.3M | 61.6M | 50.7M |
| Cash & Short-term Investments | 25.1M | 36.2M | 10.9M | 47.1M | 20.6M | 21.2M | 20.7M | 22.0M | 17.5M | 11.7M | 11.4M |
| Total Debt | 146M | 137M | 96.7M | 93.1M | 107M | 97.6M | 97.3M | 87.6M | 66.5M | 49.7M | 40.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -109K | 27.2M | 32.7M | 26.4M | 9.34M | 16.4M | 16.9M | 14.7M | 8.00M | 16.0M | 14.6M |
| Capital Expenditure | 314K | 179K | 781K | 2.56M | 44.7M | 4.51M | 10.1M | 189K | 14.3K | 209K | 80.0K |
| Free Cash Flow | -423K | 27.0M | 32.0M | 23.8M | -35.3M | 11.9M | 6.79M | 15.6M | 7.99M | 15.8M | 14.5M |
| Ratios | |||||||||||
| ROE | -3.5% | -3.4% | -15.7% | -11.0% | -9.1% | -8.2% | -18.8% | -28.2% | -27.6% | -20.5% | -14.4% |
| ROA | -3.4% | -1.6% | -8.1% | -6.1% | -5.0% | -4.8% | -9.8% | -13.2% | -12.3% | -9.2% | -6.1% |
| Net Profit Margin | -1.6% | -8.1% | -40.4% | -36.1% | -27.3% | -21.9% | -38.4% | -43.6% | -34.7% | -22.4% | -13.3% |
| Debt to Equity | 5.85x | 0.76x | 0.61x | 0.52x | 0.63x | 0.61x | 0.78x | 0.90x | 0.93x | 0.81x | 0.81x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HLS Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Apr 27, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 2.40M | 0.07 | - |
| 2022 | USD 4.96M | 0.15 | - |
| 2021 | USD 5.12M | 0.16 | - |
| 2020 | USD 4.75M | 0.15 | - |
| 2019 | USD 4.33M | 0.15 | - |
| 2018 | USD 1.05M | 0.04 | - |
| 2017 | USD 1.05M | 0.04 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns HLS Therapeutics Inc
- Insiders 0.56%
- Institutions 45.00%
- Public & others 54.44%
- Shares outstanding 30.9M
- Free float 19.1M
HLS Therapeutics Inc company profile
- Company name
- HLS Therapeutics Inc
- Ticker
- HLTRF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 85
- Fiscal year end
- December
- Address
- 10 Carlson Court, Etobicoke, ON, Canada, M9W 6L2
- Phone
- 647-495-9000
- Website
- hlstherapeutics.com
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
HLS Therapeutics Inc management
7- Mr. Craig Stuart Millian M.B.A.CEO & Director · born 1968
- Mr. John Hanna CPA, CGA, M.B.A.CFO & Non-Independent Director · born 1965
- Mr. Brian T. Walsh M.B.A.Chief Operating Officer
- Mr. Ryan C. Lennox B.A., J.D.Senior VP, General Counsel, Head of Corporate Governance & Corporate Secretary · born 1981
- Dave MasonInvestor Relations Officer
- Ms. Patricia Perry M.B.A.Vice-President of Human Resource · born 1976
- Mr. David SpenceVP & Corporate Controller · born 1968